Clinical trials: in Mali
Papillomavirus Infections, Uterine Cervical Neoplasms
Improving HPV Vaccination Coverage Among Adolescent Girls in Mali and Côte d'Ivoire Through Community Health Worker Follow-up
The goal of this trial is to learn if a community health worker (CHW) follow-up program can improve HPV vaccination coverage among adolescent girls in Mali and Côte d'Ivoire.
- Trial name
- NCT07807202
- Testing
- HPV vaccination pro-active community-based follow-up model, Standard community mobilization
- Where
- 2 sites in Côte d’Ivoire, Mali
- Volunteers
- 17,188 people
- Sponsor
- Arsène Brunelle Sandie
Motor Neuron Disease, Muscular Disease
Study of Inherited Neurological Disorders
This study is designed to learn more about the natural history of inherited neurological disorders and the role of heredity in their development.
- Conditions
- Motor Neuron Disease, Muscular Disease, Muscular Dystrophy, Peripheral Nervous System Disease
- Trial name
- NCT00004568
- Where
- 2 sites in United States, Mali
- Volunteers
- 3,500 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Malaria
Host and Parasite Factors That Influence Susceptibility to Malaria Infection and Disease During Pregnancy and Early Childhood in Ouelessebougou and Bamako, Mali
Malaria caused by Plasmodium falciparum continues to be a global problem with devastating consequences. A greater understanding of the immunologic and parasitologic factors associated with infection and disease is badly needed…
- Trial name
- NCT01168271
- Where
- 2 sites in Mali
- Volunteers
- 15,000 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
Laboratory Evaluation of Pregnancy Malaria Vaccine Candidates/In-vitro Testing of Pregnancy Malaria Vaccine Candidates
Background: Malaria is a disease that affects many people in African countries. It is caused by germs that are spread by mosquito bites. It can be fatal if not diagnosed and treated right away.
- Trial name
- NCT02471378
- Where
- Mali
- Volunteers
- 7,476 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
L9LS MAb in Malian Infants
The purpose of this study is to assess the safety, tolerability, and pharmacokinetics of L9LS in infants in Mali and to evaluate the impact of L9LS on subsequent R21/Matrix-MTM vaccine immunogenicity.
- Trial name
- NCT06461026
- Testing
- L9LS, R21/Matrix-MTM
- Where
- 3 sites in Mali
- Volunteers
- 327 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
Safety Evaluation of PfSPZ Vaccine in Pregnant Women in Mali (MalVIP1)
Background: Malaria is a disease that affects many people in Africa. It is caused by germs carried by some mosquitoes. A person bitten by an infected mosquito will get malaria.
- Trial name
- NCT05652504
- Testing
- PfSPZ Vaccine, PfSPZ Diluent, Normal Saline
- Where
- Mali
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Lassa Virus Infection
Prevalence and Incidence of Lassa Virus Infection in Southern Mali
Background: The disease Lassa fever mostly affects people in Western Africa. It is very similar to other diseases that cause fever, like malaria and yellow fever. People get Lassa fever from mice infected with Lassa virus.
- Trial name
- NCT03783143
- Where
- Mali
- Volunteers
- 8,524 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Stillbirths and Infant Mortality
Oral Azithromycin to Prevent Stillbirths and Infant Mortality in Mali
The double blind randomized controlled trial will assess the efficacy of oral azithromycin administered to pregnant women and/or infants during routine care in preventing stillbirths and mortality through 6-12 months of age in…
- Trial name
- SANTE (NCT03909737)
- Testing
- Azithromycin to pregnant women, Azithromycin to infants, No intervention to pregnant women
- Where
- Mali
- Volunteers
- 99,700 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Prevention of Malaria Transmission and Clinical Malaria
Pfs230D1 + R21 in Matrix-M1 in African School Children and Adults
This is a Phase 2, randomized, double-blind, controlled study designed to evaluate the safety, tolerability, immunogenicity, vaccine efficacy, and functional activity of Pfs230D1-CRM197 conjugate vaccine with R21 nanoparticle…
- Trial name
- NCT07147400
- Testing
- 10µg of R21 with 50µg Matrix-M1, 6µg of Pfs230D1-CRM197 + 10µg of R21 with 50µg Matrix-M1 single vial coformulation, RABIVAX-S
- Where
- Mali
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Serum Institute of India Pvt. Ltd.
Trivalent Salmonella Conjugate Vaccine (TSCV)
Trivalent Salmonella Conjugate Vaccine (TSCV)
This is an age-descending, randomized, placebo-controlled trial that will evaluate the safety and immunogenicity of a Trivalent Salmonella conjugate vaccine (TSCV).
- Trial name
- NCT05784701
- Testing
- TSCV (Full-strength), TSCV (Half-strength), Typbar-TCV
- Where
- Mali
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Meningoccocal Disease
Evaluation of the Antibody Persistence Beyond Five Years After Immunization With MenFiveTM (NmCV-5), a Pentavalent Meningococcal ACYWX Conjugate Vaccine
This study will measure immune persistence of the NmCV-5 more than 5 years after a single dose vaccination in participants 2-29 years of age in Mali and The Gambia.
- Trial name
- PERS-ACYWX-03 (NCT07379151)
- Where
- 2 sites in Mali, The Gambia
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Serum Institute of India Pvt. Ltd.
Measles Infection
Investigation of Immune Amnesia Following Measles Infection in Select African Regions
The goal of this observational study is to investigate the effects of measles virus (MeV) infection on pre-existing immunity, vaccine response, and susceptibility to subsequent illness in children aged 1-15 either with or without…
- Trial name
- NCT06153979
- Testing
- Verorab
- Where
- 2 sites in Guinea, Mali
- Volunteers
- 264 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Uncomplicated Plasmodium Falciparum Malaria
Efficacy, Safety and Tolerability of KAF156 in Combination With Lumefantrine Solid Dispersion Formulation (LUM-SDF) in Pediatric Population With Uncomplicated Plasmodium Falciparum Malaria
This study aimed to determine the efficacy, safety and tolerability of the investigational drug KAF156 in combination with a solid dispersion formulation of lumefantrine (LUM-SDF) in pediatric patients (6 months to < 18 years of…
- Trial name
- KALUMI (NCT04546633)
- Testing
- KAF156, LUM-SDF, Coartem
- Where
- 9 sites in Burkina Faso, Côte d’Ivoire and 3 more
- Volunteers
- 295 people
- Sponsor
- Novartis Pharmaceuticals
Atopic Disease
Microbiome and Atopy in Mali
This study is about allergic diseases in people living in Mali. Allergic diseases can cause health problems like asthma or skin rashes.
- Trial name
- NCT07051902
- Where
- 2 sites in Mali
- Volunteers
- 288 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
L9LS-R21 Interaction
This is a randomized, double-blind, placebo-controlled trial in 2 parts evaluating the effect of 1-time administration of the monoclonal antibody (MAb) L9LS to healthy Malian participants on the immunogenicity of subsequent…
- Trial name
- NCT07208760
- Testing
- Single dose of 1800 mg L9LS SC (12mL), Single dose of 225 mg L9LS SC (1.5mL)
- Where
- Mali
- Volunteers
- healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
Assessment of Safety and Immunogenicity of a Single Vial Presentation of R21/Matrix-M and Co-Administration With EPI Vaccines
This is a Phase Ib trial conducted in Bougouni, Mali to evaluate the safety and immunogenicity of R21/Matrix-M in a single and two vial presentation, with different immunisation schedules, and when co-administered with EPI…
- Trial name
- NCT05155579
- Testing
- R21/Matrix-M - single vial formulation, R21/Matrix-M - two vial formulation, Licensed vaccine - Measles-rubella
- Where
- 2 sites in Mali, United Kingdom
- Volunteers
- 594 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Meningitis
Meningococcal Serogroup ACYWX Conjugate Vaccine in Comparison With MenACWY-TT Conjugate Vaccine
Infants aged 9 months will be randomized to receive a meningococcal vaccine at 9 months or 15 months. Infants randomized to the 9-month age group will be further randomized in a 2:1 ratio to receive a single dose of the…
- Trial name
- NCT05093829
- Testing
- NmCV-5, MenACWY-TT
- Where
- Mali
- Volunteers
- 1,325 people, healthy volunteers welcome
- Sponsor
- Emory University
Malaria, Pregnancy Related
Pregnancy Registry in Mali
This registry will assess pregnancy outcomes through demographic surveillance and prospective data collection at a health facility in Kalifabougou, Mali.
- Trial name
- NCT06468319
- Where
- Mali
- Volunteers
- 9,500 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Nephroblastoma
Therapeutic Recommendations for Nephroblastoma
The study is based on results form 2 previous studies carried out by the GFAOP. The aim of this study is to evaluate the capacity of units to follow the recommendations in the protocol.
- Trial name
- GFANEPHRO20 (NCT04423484)
- Testing
- Data collection
- Where
- 7 sites in Burkina Faso, Côte d’Ivoire and 4 more
- Volunteers
- 1,000 people
- Sponsor
- French Africa Pediatric Oncology Group
Burkitt Lymphoma
Recommendations for the Treatment of Children With Burkitt's Lymphoma
This is the 4th LMB study by the French African Pediatric Oncology Group (GFAOP). The study hopes to be able to evaluate children earlier with stage I and II disease and to evaluate treatment response earlier so that the units…
- Trial name
- GFALMB2019 (NCT04425421)
- Testing
- OBSERVATIONAL
- Where
- 7 sites in Burkina Faso, Côte d’Ivoire and 4 more
- Volunteers
- 1,000 people
- Sponsor
- French Africa Pediatric Oncology Group